Dehmel & Bettenhausen

The present invention relates to methods for obtaining an expanded population of skeletal muscle derived cells (SMDC). The present invention also refers to an expanded population of SMDCs obtained by the method according to the present invention and to an expanded population of SMDCs. Further, the present invention refers to an expanded population of SMDCs for use in a method for treatment of the human or animal body by surgery or therapy or for use as a pharmaceutical composition. In addition, the present invention refers to an expanded population of SMDCs for use in a method of preventing and/or treating neuromyopathies, myopathies and/or muscle dysfunctions such as a urinary and/or an anal incontinence.

A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

The present invention refers to a device for processing a fluid by centrifugation and/or sedimentation comprising: a syringe body a syringe plunger comprising a sealing plate and a perforated sealing plate at the lower end of the plunger, wherein the perforated sealing plate is movably attached to the syringe plunger and the distance between the movable perforated sealing plate and the sealing plate is variable, and a syringe closure, comprising at least one perforation cage. The present invention also refers to a syringe plunger and a syringe closure of a device according to the present invention. Moreover, the present invention refers to a method of processing a fluid. In addition, the present invention refers to a use of the device, the syringe plunger, the syringe closure or the method according to the present invention for the clean and lossless release of individual phases of multiphase fluids after separation using centrifugal or gravitational forces, in particular for separating a fluid into two, three or more phases, for enriching cells in a fat graft or bone marrow, for homogenizing a fat graft and/or for processing whole blood.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

The disclosure relates to an (isolated) antibody (or antibody fragment/antigen binding fragment thereof) binding to (human) HMGI-C (anti-HMGI-C-Antibody) as well the nucleic acid encoding such an antibody or host cells comprising these or pharmaceutical composition comprising the antibody. Preferred antibodies are binding to the epitopes of SEQ. ID NOs. 32, 33 or 34, especially the (monoclonal) antibodies that comprise in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 4; in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 14; or in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 24. Especially preferred are also the (monoclonal) antibodies that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 1 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 6; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 11 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 16; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 21 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 26. In addition, the disclosure relates to a lateral flow device for the detection of HMGI-C, especially the HMGI-C released during an event leading to an acute aortic syndrome/acute aortic dissection (AAS/AAD) or in relation to cancer in a sample of bodily fluid of a human/patient using an antibody of the disclosure or to the use of the antibody for the treatment of cancer or for cancer prevention by early detection of HMGI-C as a marker for cancer.